Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Check this box if no longer subject	STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP
to Section 16. Form 4 or Form 5		
obligations may continue. See		

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* LASEZKAY GEORGE M					2. Issuer Name and Ticker or Trading Symbol Clearside Biomedical, Inc. [CLSD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner											wner			
l		rst) (t BIOMEDICAL, 1 F PARKWAY, SU		00		3. Date of Earliest Transaction (Month/Day/Year) 12/21/2020								X	Office belov	er (give title w) CEO		Other (specify below)	
(Street) ALPHA (City)	RETTA GA		30005 Zip)		4. If <i>i</i>								6. Indi Line) X	'					
		Table	I - No	n-Deriva	ative S	Secu	rities	Acq	uired,	, Dis	posed of	, or E	Benef	icially	/ Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day			Execution (Many)		Deemed ecution Date, ny onth/Day/Year)		3. Transaction Code (Instr. 8) 4. Securitie Disposed Code (5)				4 and Securi Benefi		ties cially I Following	Form (D) o	wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership			
										v	Amount	(A) (D)	or Pi	ice	Transa	action(s) 3 and 4)			(Instr. 4)
Common Stock 12/21/				2020			S ⁽¹⁾		3,330	3,330 D \$		2.07(2))7 ⁽²⁾ 299,359			D			
		Tal	ble II -						,		osed of, convertib			•	Owne	d	•	,	
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		Code (8)	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4) Amoun or Numbo of Title Shares		unt ber		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

- 1. The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.069 to \$2.074, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Mark Ballantyne, Attorney-12/23/2020 in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.